Brain Metastases

Understanding Brain Metastases

The development of brain metastases represents a critical turning point in cancer management, with significant implications for both neurological function and overall survival. Tumour cells from the primary site enter the systemic circulation, traverse the blood-brain barrier, and establish secondary deposits within the brain parenchyma. The most common locations are at the grey-white matter junction, where the vascular architecture favours embolic seeding. Metastases are frequently multiple — 50 per cent of patients present with more than one lesion — and their growth compresses surrounding brain tissue, producing oedema, mass effect, and progressive neurological deficits.

Advances in stereotactic radiosurgery have transformed the prognosis for patients with brain metastases. Gamma Knife treatment achieves local control rates exceeding 90 per cent with minimal cognitive impact, compared to whole-brain radiotherapy which carries significant neurocognitive side effects. For international patients, Istanbul provides rapid access to Gamma Knife treatment, enabling cancer patients to begin their intracranial treatment without delay.

Symptoms of Brain Metastases

The presentation of brain metastases depends on the number, size, and location of the lesions. Headache is the most common presenting symptom, occurring in 50 per cent of patients, and is often worse in the morning or exacerbated by coughing and straining. Seizures occur in 20–30 per cent of patients, particularly with supratentorial cortical metastases. Focal neurological deficits — hemiparesis, aphasia, visual field cuts, sensory loss — correspond to the affected brain region. Cognitive changes, personality changes, and gait disturbance are common in patients with multiple or large metastases. Nausea and vomiting may indicate raised intracranial pressure.

Diagnostic Pathways

MRI with gadolinium contrast is the imaging modality of choice. Brain metastases typically appear as well-circumscribed, ring-enhancing lesions at the grey-white matter junction with surrounding vasogenic oedema. T2-weighted and FLAIR sequences best demonstrate the extent of peritumoural oedema. CT with contrast is a reasonable alternative but has lower sensitivity for small metastases and posterior fossa lesions. Whole-body PET-CT and CT chest/abdomen/pelvis are performed to identify the primary tumour and assess the overall disease burden. Lumbar puncture for CSF cytology is reserved for suspected leptomeningeal disease.

Advanced Treatment Options at Vellum Select

Vellum Select provides comprehensive brain metastasis management through Prof. Dr. Türker Kılıç, integrating Gamma Knife radiosurgery with modern oncological protocols.

Gamma Knife Radiosurgery

For patients with a limited number of brain metastases (typically 1–10 lesions), Gamma Knife Radiosurgery in Turkey is the standard of care. Gamma Knife delivers high-dose radiation to each metastasis in a single outpatient session, sparing the surrounding normal brain tissue. Local control rates at one year exceed 90 per cent, and treatment can be repeated for new lesions. Unlike whole-brain radiotherapy, Gamma Knife preserves cognitive function and quality of life. The procedure is non-invasive, requires no incision, and patients return home the same day.

Surgical Resection

For large metastases (over 3 cm) causing significant mass effect, or when histological diagnosis is required, Craniotomy (Brain Surgery) in Turkey with microsurgical resection is performed. Post-operative Gamma Knife to the resection cavity reduces the risk of local recurrence to under 10 per cent.

To discuss your brain metastasis diagnosis with Prof. Dr. Türker Kılıç, view his profile or contact Vellum Select to arrange a consultation.